Waterdrop Inc. Reports Unaudited Financial Results for Q1 2023

PRNewswireJune 5, 202334 min

Waterdrop Inc. (“Waterdrop”, the “Company” or “we”) (NYSE:¬†WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the first quarter ended¬†March 31, 2023.

Financial and Operational Highlights for the First Quarter of 2023

  • Resilient Business Performance: For the first quarter of 2023, the first-year premiums (“FYP”) generated through our Waterdrop Insurance Marketplace amounted to¬†RMB1,692.0 million¬†(US$246.4 million), representing an increase of 6.3% quarter over quarter. Our net operating revenue was¬†RMB606.2 million¬†(US$88.3 million), representing a decrease of 10.8% quarter over quarter.
  • Effective cost control and sustained profitability: For the first quarter of 2023, our operating costs decreased by 11.0%, and total operating costs and expenses decreased by 1.8% quarter over quarter. Our net profit reached¬†RMB49.7 million¬†(US$7.2 million), continuing the trend in profitability since the beginning of 2022. Our solid financial performance highlights our achievements in cost control and profit enhancement.
  • Positive operating cash flow: As of¬†March 31, 2023, our cash and cash equivalents and short-term investments balance amounted to¬†RMB3,597.3 million¬†(US$523.8 million). We continued to generate positive operating cash flow, and have cash outflow of investing and financing activities.
  • Further expanded product offerings: As of¬†March 31, 2023, we offered 876 insurance products on our platform, as compared with 775 as of¬†December 31, 2022. In the first quarter of 2023, the FYP generated from critical illness insurance products accounted for 26.9% of overall FYP generated through our Waterdrop Insurance Marketplace.
  • As of¬†March 31, 2023, around 432 million people cumulatively had donated an aggregate of approximately¬†RMB58.4 billion¬†to over 2.86 million patients through Waterdrop Medical Crowdfunding.

Mr.¬†Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, “In the first quarter, we continued to demonstrate resilient and high-quality development, with net operating revenue reaching¬†RMB606.2 million. Moreover, we are proud to have achieved another quarter of profitability. Our net profit reached¬†RMB49.7 million, which again showcased our consistent efforts towards building a pattern of sustainable and high-quality business growth.

For our insurance business, we further optimized our user acquisition strategies during the first quarter and saw a quarterly increase in the number of new users. Meanwhile, we continually streamlined channel operations and improved our service quality. As a result, our renewal rate sustained at a high level. We also continued to enrich our product offerings, including tailored products for specific user groups, specially the underaged and the elderly. On the technology side, we further upgraded our AI-empowered dialogue robot,.which can now conduct a ten-minute call independently and is expected to help accelerate business development to a greater extent.

As for the medical crowdfunding business, we have focused on optimizing and improving our operational capabilities. By adjusting risk control strategies, we have basically eliminated cases with unreasonable fundraising targets. Our Operational Transparency Committee has also established a mechanism to examine service processes and improve the practice of consultants. Meanwhile, we continued to actively collaborate with multiple parties to crack down on dishonest fundraising practices. This year, we were honored as the “Consumer New Force” Integrity Commitment Enterprise at the Integrity Beijing 3.15 Gala.

In terms of clinical trial solution business, as the impact of the pandemic and holidays gradually subsided, E-find Patient Platform showed continued growth. In the first quarter, we successfully enrolled over 700 patients and launched more than 70 clinical trial programs, boosting the progress of drug development for over 120 pharmaceutical companies and CROs. E-find Patient Platform maintained competitive in the field of oncology while consciously exploring other diseases, including but not limited to psoriasis, atopic dermatitis, and asthma.

Moving forward, we will continue to play an active role in promoting the multi-level diversification of medical payment system in¬†China¬†and empowering Chinese insurance and healthcare industry participants. ”

Financial Results for the First Quarter of 2023

Operating revenue, net

Net operating revenue for the first quarter of 2023 decreased by 6.6% year over year to RMB606.2 million (US$88.3 million) from RMB648.7 million for the same period of 2022.

  • Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to¬†RMB536.3 million¬†(US$78.1 million) in the first quarter of 2023, representing a decrease of 14.6% year over year from¬†RMB628.2 million¬†for the first quarter of 2022, which was mainly due to the decrease in insurance brokerage income.
  • Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the “medical crowdfunding services”). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. Since¬†April 7, 2022, our crowdfunding platform has ceased to fully subsidize the related cost and started to charge a service fee of 3% of the funds raised, up to a maximum amount of¬†RMB5,000¬†for a single campaign. Considering the specific situation of each case, we may selectively subsidize the service fee for certain extremely needy patients. For the first quarter of 2023, we generated¬†RMB42.0 million¬†(US$6.1 million) in service fees, as compared to nil in the same period of 2022.
  • Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the first quarter of 2023, our clinical trial solution income amounted to¬†RMB22.8 million¬†(US$3.3 million), as compared to¬†RMB8.6 million¬†in the same period of 2022.

Operating costs and expenses

Operating costs and expenses increased by 12.0% year over year to RMB595.8 million (US$86.8 million) for the first quarter of 2023. On a quarter-over-quarter basis, operating costs and expenses decreased by 1.8%.

  • Operating costs increased by 60.1% year over year to¬†RMB248.0 million¬†(US$36.1 million) for the first quarter of 2023, as compared with¬†RMB154.9 million¬†for the first quarter of 2022, which was primarily driven by (i) a¬†RMB29.1 million¬†increase in professional and outsourced customer service fees, (ii) an increase of¬†RMB61.5 million¬†mainly due to recording the crowdfunding consultants team costs as operating costs rather than as sales and marketing expense, as we started to generate crowdfunding service fees since¬†April 2022, and (iii) a¬†RMB8.9 million¬†increase in the costs for patient recruitment consultants team. On a quarter-over-quarter basis, operating costs decreased by 11.0% in the first quarter of 2023, primarily due to the¬†RMB25.9 million¬†decrease in professional and outsourced customer service fees.
  • Sales and marketing expenses decreased by 15.1% year over year to¬†RMB173.4 million¬†(US$25.2 million) for the first quarter of 2023, as compared with¬†RMB204.3 million¬†for the same quarter of 2022. The decrease was primarily due to (i) a decrease of¬†RMB61.5 million¬†in crowdfunding related direct costs recorded from under sales and marketing expenses to under operating costs as above mentioned, partially offset by (i) a¬†RMB19.8 million¬†increase in marketing expenses to third-party traffic channels, and (ii) a¬†RMB24.9 million¬†increase in personnel cost. On a quarter-over-quarter basis, sales and marketing expenses increased by 25.8% in the first quarter of 2023, primarily due to the¬†RMB29.4 million¬†increase in marketing expenses to third-party traffic channels.
  • General and administrative expenses decreased by 6.1% year over year to¬†RMB95.8 million¬†(US$13.9 million) for the first quarter of 2023, compared with¬†RMB102.0 million¬†for the same quarter of 2022. The year-over-year variance was due to a decrease of¬†RMB16.3 million¬†allowance for doubtful accounts, partially offset by a¬†RMB9.3 million¬†increase in personnel cost. On a quarter-over-quarter basis, general and administrative expenses decreased by 19.2% in the first quarter of 2023, primarily due to (i)¬†RMB19.7 million¬†decrease in allowance for doubtful accounts, and (ii)¬†RMB8.2 million¬†decrease in professional service fees.
  • Research and development expenses increased by 11.2% year over year to¬†RMB78.7 million¬†(US$11.5 million) for the first quarter of 2023, compared with¬†RMB70.8 million¬†for the same period of 2022. The increase was primarily due to¬†RMB10.1 million¬†increases in research and development personnel costs and share-based compensation expenses. On a quarter-over-quarter basis, research and development expenses increased by 9.8% from¬†RMB71.7 million, which was mainly due to¬†RMB7.0 million¬†increases in research and development personnel costs and share-based compensation expenses.

Operating profit for the first quarter of 2023 was RMB10.3 million (US$1.5 million), as compared with an operating profit of RMB116.6 million for the first quarter of 2022 and a profit of RMB72.9 million for the fourth quarter of 2022.

Interest income for the first quarter of 2023 was RMB30.9 million (US$4.5 million), as compared with RMB14.5 million for the same period of 2022. The increase was primarily due to the increase in our short-term investments.

Income tax benefit for the first quarter of 2023 was RMB2.6 million (US$0.4 million), as compared with an income tax expense of RMB51.3 million for the same period of 2022.

Net profit attributable to Waterdrop for the first quarter of 2023 was RMB49.7 million (US$7.2 million), as compared with a net profit of RMB105.0 million for the same period of 2022, and a net profit of RMB126.2 million for the fourth quarter of 2022.

Adjusted net profit attributable to Waterdrop for the first quarter of 2023 was RMB96.4 million (US$14.0 million), as compared with an adjusted net profit of RMB127.3 million for the same period of 2022, and an adjusted net profit of RMB159.7 million for the fourth quarter of 2022.

Cash and cash equivalents and short-term investments

As of March 31, 2023, the Company had combined cash and cash equivalents and short-term investments of RMB3,597.3 million (US$523.8 million), as compared with RMB3,704.5 million as of December 31, 2022.

Share Repurchase Plan

Pursuant to the share repurchase program launched in September 2021 and amended in September 2022, as of May 31, 2023, we cumulatively repurchased approximately 24.9 million ADSs from the open market with cash for a total consideration of approximately US$61.2 million.

Exchange Rate

This announcement contains translations of certain RMB amounts into U.S. dollars (“USD” or “US$”) at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB¬†to USD were made at the rate of¬†RMB6.8676¬†to¬†US$1.00, the noon buying rate in effect on March¬†31, 2023¬†in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB¬†or USD amounts referred could be converted into USD or RMB, as the case may be, at any particular rate or at all. For analytical presentation, all percentages are calculated using the numbers presented in the financial statements contained in this earnings release.

Non-GAAP Financial Measures

The Company uses¬†non-GAAP financial measure, adjusted net profit, in evaluating the Company’s operating results and for financial and operational decision-making purposes. Adjusted net profit represents net profit excluding share-based compensation expense¬†and foreign currency exchange gain or losses. Such adjustments have no impact on income tax.

The non-GAAP financial measure is¬†not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measure has¬†limitations as analytical tools and when assessing the Company’s operating performance, investors should not consider it in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. Investors are encouraged to review the Company’s historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted net profit presented here may not be comparable to similarly titled measure presented by other companies. Other companies may calculate similarly titled measure differently, limiting¬†its¬†usefulness as a comparative measure to our data.

The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.

For more information on the non-GAAP financial measures, please see the table captioned “Reconciliation of GAAP and Non-GAAP Results” set forth at the end of this press release.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Among other things, quotations in this announcement, contain forward-looking statements. Waterdrop may also make written or oral forward-looking statements in its periodic reports to the¬†Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Waterdrop’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Waterdrop’s mission, goals and strategies; Waterdrop’s future business development, financial condition and results of operations; the expected growth of the insurance, medical crowdfunding and healthcare industry in¬†China; Waterdrop’s expectations regarding demand for and market acceptance of our products and services; Waterdrop’s expectations regarding its relationships with consumers, insurance carriers and other partners; competition in the industry and relevant government policies and regulations relating to insurance, medical crowdfunding and healthcare industry. Further information regarding these and other risks is included in Waterdrop’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Conference Call Information

Waterdrop’s management team will hold a conference call on¬†June 2, 2023¬†at¬†8:00 AM¬†U.S. Eastern Time (8:00 PM¬†Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

International:

1-412-317-6061

United States Toll Free:

1-888-317-6003

Hong Kong Toll Free:

800-963976

Hong Kong:

852-58081995

Mainland China:

4001-206115

Chinese Line (Mandarin) Entry Number:

6683992

English Interpretation Line (Listen-only Mode) Entry Number:

8700524

Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

Telephone replays will be accessible two hours after the conclusion of the conference call through June 9, 2023 by dialing the following numbers:

United States Toll Free:

1-877-344-7529

International:

1-412-317-0088

Chinese Line Access Code:

1702325

English Interpretation Line Access Code:

8201572

Fintech News РThe Latest News in Financial Technology.

PRNewswire

newOriginal-white-FinTech1-1

We are one of the world’s leading Fintech-based media publication with our content strategized and synthesized to fit right into the expanding ecosystem of Finance professionals. Be it fintech live news, finance press releases, tech articles from Fintech evangelists or interviews from top leaders from global fintech firms, we give the best slice of knowledge topped up with the aptest trends. Our sole mission is to help tech and finance professionals step up with the rapidly emerging Fintech civilization and gain better insights to emerge victorious in every possible way. We adopt a 360-degree approach in order to cater to present a holistic picture of the fintech arena.

Our Publications



FintecBuzz, 2023 © All Rights Reserved